



Pharmacologic Agents for Treatment of Type 2 Diabetes

SCAN Formulary Drugs

Medication	2025 Formulary		2026 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Biguanides							
<i>metformin tabs</i>	1		1		500 – 850 mg QD - QID	Neutral	Nausea/ vomiting, GI upset, metallic taste, diarrhea, flatulence, lactic acidosis (rare)
<i>metformin er uncoated tabs</i> 500 mg & 750 mg	1		1		500 – 2000 mg daily		Nausea/ vomiting, GI upset, diarrhea, flatulence, lactic acidosis
Sulfonylureas							
<i>glimepiride</i>	1		1		1 – 8 mg daily	Moderate	Dizziness, headache, hypoglycemia, nausea, weight gain
<i>glipizide</i>	1		1		2.5 – 20 mg daily		Rash, diarrhea, dizziness, headache, diarrhea, hypoglycemia, nausea, weight gain
<i>glipizide er</i>	1		1		5 – 20 mg daily		Asthenia, headache, dizziness, rash, nausea, hypoglycemia, weight gain
<i>glipizide / metformin tabs</i>	1		1		2.5 / 500 mg QID	Moderate	Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
Thiazolidinediones & Thiazolidinedione Combination Agents							
<i>pioglitazone</i>	1		1		15 – 45 mg daily	Neutral	Anemia, edema, weight gain, headache, myalgia, bone fracture, heart failure
<i>pioglitazone / metformin</i>	2		2		15 / 500 mg – 45 / 1500 mg daily		Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
<i>pioglitazone / glimepiride</i>	2	[QL]	2		15 / 500 mg – 45 / 2550 mg daily		Anemia, edema, weight gain, headache, myalgia, dizziness, hypoglycemia, nausea



Alpha-Glucosidase Inhibitor							
<i>acarbose</i>	2		2		25 – 100 mg TID administered at the start of each meal to decrease postprandial glucose peaks	Neutral	Abdominal pain, diarrhea, flatulence, elevated serum transaminases
Meglitinides							
<i>nateglinide</i>	2		2		60 – 120 mg TID before meals	Moderate	Dizziness, arthralgia, diarrhea, hypoglycemia, weight gain, increased uric acid
<i>repaglinide</i>	2		2		0.5 – 4 mg TID before meals		Hypoglycemia, arthralgia, diarrhea, weight gain
DPP-4s (Dipeptidyl Peptidase-4 Inhibitors)							
JANUMET, JANUMET XR (<i>sitagliptin / metformin</i>)	3	[QL]	3	[QL]	100 / 2000 mg daily	Neutral	Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, flatulence, lactic acidosis, pancreatitis
JANUVIA (<i>sitagliptin</i>)	3	[QL]	3	[QL]	100 mg daily	Neutral	Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, URI, pancreatitis
JENTADUETO (<i>linagliptin / metformin</i>)	3	[QL]	3	[QL]	2.5 / 1000 mg BID	Neutral	Nasopharyngitis hypoglycemia, cough, diarrhea
JENTADUETO XR (<i>linagliptin / metformin</i>)	3	[QL]	3	[QL]	5 / 2000 mg daily	Neutral	Nasopharyngitis hypoglycemia, cough, diarrhea
<i>saxagliptin</i>	NF		3	[QL]	2.5 – 5 mg daily	Neutral	Abdominal pain, diarrhea, URI, pancreatitis, nausea, hypoglycemia
<i>saxagliptin / metformin</i>	NF		3	[QL]	Individualize dose; 5 / 2000 mg daily max	Neutral	Nausea/ vomiting, GI upset, asthenia, diarrhea, flatulence, lactic acidosis, pancreatitis



TRADJENTA (<i>linagliptin</i>)	3	[QL]	3	[QL]	5 mg daily	Neutral	Hypoglycemia, diarrhea, cough, nasopharyngitis, arthralgia
TRIJARDY XR (<i>empagliflozin / linagliptin / metformin</i>)	3	[QL]	3	[QL]	25 / 5 / 2000 mg daily	Neutral	Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis
Insulins							
	Vial	Pen	Vial	Pen			
ADMELOG (insulin lispro)	NF	NF	NF	NF			
APIDRA (insulin glulisine)	NF	NF	NF	NF			
BASAGLAR (insulin glargine)	NF	NF	NF	NF			
FIASP (<i>insulin aspart</i>)	NF	NF	3	3			
HUMALOG (<i>insulin lispro</i>)	3	3	3	3			
HUMALOG MIX 50/50, 75/25 (<i>insulin lispro / protamine</i>)	3	3	3	3	Patient specific dosing applies	Neutral	Hypoglycemia, injection site reaction, lipodystrophy, hypokalemia
HUMULIN 70/30 (<i>insulin human-regular / NPH</i>)	3	3	3	3			
HUMULIN N (<i>insulin NPH</i>)	3	3	3	3			
HUMULIN R (<i>insulin human-regular</i>)	3	-	3	-			
HUMULIN R U-500 (<i>insulin human-regular</i>)	3	3	3	3			
INSULIN GLARGINE	NF	NF	NF	NF			
INSULIN LISPRO	3	3	3	3			

R. Brower and N. Nguyen rev. 11/2012; R. Brower rev. 11/2013, 9/2014, 11/2015; D. Yoon rev. 8/2016, 11/2016, 8/2017; K. Truong rev. 9/2018; D. Yoon rev. 9/2019, 8/2020; S. Cho rev. 9/2021; D. Yoon rev. 9/2022; S. Cho rev. 9/2023, 9/2024; K. Truong 9/2025



INSULIN LISPRO / PROTAMINE	-	NF	-	3			
LANTUS (<i>insulin glargine</i>)	3	3	3	3			
LYUMJEV (<i>insulin lispro</i>)	3	3	3	3			
MERIOLOG (<i>insulin aspart</i>)	NF	NF	NF	NF			
NOVOLIN (<i>insulin human-regular</i>)	NF	NF	3	3			
NOVOLIN N (<i>insulin NPH</i>)	NF	NF	3	3			
NOVOLIN R (<i>insulin human-regular</i>)	NF	NF	3	3			
NOVOLOG (<i>insulin aspart</i>)	NF	NF	3	3			
NOVOLOG MIX (<i>insulin aspart human / protamine</i>)	NF	NF	3	3			
TOUJEO / TOUJEO MAX (<i>insulin glargine</i>)	-	3	-	3			
TRESIBA (<i>insulin degludec</i>)	3	3	3	3			
GIP/GLP-1 Agonist (Glucose-dependent Insulinotropic Polypeptide / Glucagon-Like Peptide-1)							
MOUNJARO (<i>tirzepatide</i>)	3	[PA] [QL]	3	[PA] [QL]	5 mg to 15 mg SC weekly	Neutral	Diarrhea, nausea, vomiting, headache, abdominal pain, constipation
Insulin/GLP-1 Agonist Combination							
SOLIQUA (<i>insulin glargine / lixisenatide</i>)	-	3	-	3	15 units to 60 units SC daily	Neutral	Hypoglycemia, diarrhea, nausea, vomiting, headache, pancreatitis



GLP-1 Agonist (Glucagon-Like-Peptide-1)							
BYDUREON BCISE (<i>exenatide er</i>)	3	[PA] [QL]	NF		2 mg SC weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
<i>liraglutide</i>	NF		4	[PA] [QL]	0.6 mg – 1.8mg SC daily	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
OZEMPIC (<i>semaglutide</i>)	3	[PA] [QL]	3	[PA] [QL]	0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
RYBELSUS (<i>semaglutide</i>)	3	[PA] [QL]	3	[PA] [QL]	0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
TRULICITY (<i>dulaglutide</i>)	3	[PA] [QL]	3	[PA] [QL]	0.75 – 1.5 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
Amylinomimetic							
SYMLIN PEN (<i>pramlintide</i>)	5		5		60 mcg – 120 mcg SC prior to main meals	Neutral	Nausea, anorexia, dizziness, fatigue
SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2)							
FARXIGA (<i>dapagliflozin</i>)	3	[QL]	3	[QL]	5 – 10 mg daily	Neutral	Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea
<i>dapagliflozin</i>	NF		3	[QL]	5 – 10 mg daily	Neutral	Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea
GLYXAMBI (<i>empagliflozin / linagliptin</i>)	3	[QL]	3	[QL]	10 / 5 – 25 / 5 mg daily	Neutral	Urinary tract infections, nasopharyngitis, hypoglycemia, cough, diarrhea, upper respiratory tract infections
JARDIANCE (<i>empagliflozin</i>)	3	[QL]	3	[QL]	10 – 25 mg daily	Neutral	Urinary tract infections and female genital mycotic infections



SYNJARDY <i>(empagliflozin / metformin)</i>	3	[QL]	3	[QL]	12.5 / 1000 mg BID	Neutral	Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
SYNJARDY XR <i>(empagliflozin / metformin)</i>	3	[QL]	3	[QL]	25 / 2000 mg daily	Neutral	Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
XIGDUO XR <i>(dapagliflozin / metformin)</i>	3	[QL]	3	[QL]	5 / 500 – 10 / 2000 mg daily	Neutral	Low vitamin-B12, diarrhea, headache, UTI, genital mycotic infection, nasopharyngitis
Mineralcorticoid Receptor Antagonist							
KERENDIA <i>(finerenone)</i>	3	[PA]	3	[PA]	20 mg daily	Neutral	Hypotension, hyponatremia, hyperkalemia

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[PA] = Prior Authorization [QL] = Quantity Limit

* 2019 AACE/ACE Consensus Statement



Diabetes Guidelines References

SCAN Health Plan Diabetes Guidelines adapted from:

- American Diabetes Association; Standards of Medical Care in Diabetes-2025: Diabetes Care December 2024, Vol.48, S1-S5. doi:<https://doi.org/10.2337/dc25-SINT> (Accessed 9/22/2025)
- Summary of Revisions: Standards of Medical Care in Diabetes 2025. Diabetes Care 2024;48(Suppl. 1):S6–S13 | <https://doi.org/10.2337/dc25-SREV>
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrine Practice. (2020, January). Vol. 26, No. 1, pp. 107-139.
- Drug Facts & Comparisons. (2025, Sept). Retrieved from www.online.factsandcomparisons.com. Wolters Kluwer Health: Deventer, TheNetherlands.
- Epocrates Online (2023, Sept). Retrieved from: <http://online.epocrates.com>. Epocrates, Inc.: San Mateo, California.
- Reuben, D. B., Herr, K. A., Pacala, J. T., Pollock, B. G., Potter, J. F., & Semla, T. P. (2015). Geriatrics at your fingertips. 17th ed. (Based on AGS Guidelines.)
- Online Lexicomp (09/2025): 1100 Terex Road, Hudson, OH 44236